SF3B3 Protein, Human (sf9)

SF3B3 protein is a key splicing factor in the SF3B complex and plays a central role in pre-mRNA splicing. It is essential for "A" complex assembly and stabilizes U2 snRNP binding to branch point sequences. SF3B3 Protein, Human (sf9) is the recombinant human-derived SF3B3 protein, expressed by sf9 insect cells , with tag free.

SF3B3 protein plays a critical role in pre-mRNA splicing as an integral component of the splicing factor SF3B complex, a key constituent of the spliceosome. This complex is essential for the assembly of the 'A' complex, facilitating the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA. SF3B3's sequence-independent binding with SF3A/SF3B complex upstream of the branch site anchors U2 snRNP to the pre-mRNA, highlighting its pivotal role in splicing initiation. Additionally, SF3B3 may contribute to the assembly of the 'E' complex and is involved in the splicing of U12-type introns as a part of the minor spliceosome. Identified in various spliceosome complexes, including A, B, C, and E complexes, SF3B3 remains associated with the spliceosome throughout the splicing process. Within the SF3B complex, SF3B3 interacts directly with SF3B1, SF3B5, and PHF5A, demonstrating its involvement in the intricate machinery of splicing regulation. The interaction of SF3B3 with U2AF2 further underscores its role in coordinating splicing events. Additionally, SF3B3 associates with the STAGA transcription coactivator-HAT complex, interacting with SUPT3H and TAF3, further expanding its functional repertoire beyond splicing.

Human

Sf9 insect cells

Tag Free

Q15393 (F2-F1217)

23450

Partial

FLYNLTLQRATGISFAIHGNFSGTKQQEIVVSRGKILELLRPDPNTGKVHTLLTVEVFGVIRSLMAFRLTGGTKDYIVVGSDSGRIVILEYQPSKNMFEKIHQETFGKSGCRRIVPGQFLAVDPKGRAVMISAIEKQKLVYILNRDAAARLTISSPLEAHKANTLVYHVVGVDVGFENPMFACLEMDYEEADNDPTGEAAANTQQTLTFYELDLGLNHVVRKYSEPLEEHGNFLITVPGGSDGPSGVLICSENYITYKNFGDQPDIRCPIPRRRNDLDDPERGMIFVCSATHKTKSMFFFLAQTEQGDIFKITLETDEDMVTEIRLKYFDTVPVAAAMCVLKTGFLFVASEFGNHYLYQIAHLGDDDEEPEFSSAMPLEEGDTFFFQPRPLKNLVLVDELDSLSPILFCQIADLANEDTPQLYVACGRGPRSSLRVLRHGLEVSEMAVSELPGNPNAVWTVRRHIEDEFDAYIIVSFVNATLVLSIGETVEEVTDSGFLGTTPTLSCSLLGDDALVQVYPDGIRHIRADKRVNEWKTPGKKTIVKCAVNQRQVVIALTGGELVYFEMDPSGQLNEYTERKEMSADVVCMSLANVPPGEQRSRFLAVGLVDNTVRIISLDPSDCLQPLSMQALPAQPESLCIVEMGGTEKQDELGERGSIGFLYLNIGLQNGVLLRTVLDPVTGDLSDTRTRYLGSRPVKLFRVRMQGQEAVLAMSSRSWLSYSYQSRFHLTPLSYETLEFASGFASEQCPEGIVAISTNTLRILALEKLGAVFNQVAFPLQYTPRKFVIHPESNNLIIIETDHNAYTEATKAQRKQQMAEEMVEAAGEDERELAAEMAAAFLNENLPESIFGAPKAGNGQWASVIRVMNPIQGNTLDLVQLEQNEAAFSVAVCRFSNTGEDWYVLVGVAKDLILNPRSVAGGFVYTYKLVNNGEKLEFLHKTPVEEVPAAIAPFQGRVLIGVGKLLRVYDLGKKKLLRKCENKHIANYISGIQTIGHRVIVSDVQESFIWVRYKRNENQLIIFADDTYPRWVTTASLLDYDTVAGADKFGNICVVRLPPNTNDEVDEDPTGNKALWDRGLLNGASQKAEVIMNYHVGETVLSLQKTTLIPGGSESLVYTTLSGGIGILVPFTSHEDHDFFQHVEMHLRSEHPPLCGRDHLSFRSYYFPVKNVIDGDLCEQFNSMEPNKQKNVSEELDRTPPEVSKKLEDIRTRYAF

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.